Biological Availability Clinical Trial
— BIOPTERO2Official title:
Evaluation of the Oral Bioavailability of a New Formulation of Pterostilbene Co-crystal in Comparison With Its Free Form in Healthy Volunteers: Crossover, Randomized and Simple Blind Study (BIOPTERO2)
NCT number | NCT06289140 |
Other study ID # | BIOPTERO2 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 11, 2024 |
Est. completion date | May 7, 2024 |
Verified date | June 2024 |
Source | Fundació Eurecat |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this interventional study is to to evaluate the oral bioavailability of the crystallized form of pterostilbene (ccPT) compared to its commercial free base form (pterostilbene (PT) in healthy volunteers. The main question it aims to answer are: • Do the crystallized forms of pterostilbene (ccPT) using two different encapsulation methods exhibit greater bioavailability than its commercial free base form (PT)? Participants will attend to four visits: a preselection visit (V0), a visit for the first postprandial study (V1), a visit for the second postprandial study (V2) after one-week washing period and a visit for the third postprandial study (V3) after another one week washing period. Researchers will analyze the three postprandial assays to determine which type of ccPT encapsulation provides the highest bioavailability compared to the commercial free base form (PT).
Status | Completed |
Enrollment | 6 |
Est. completion date | May 7, 2024 |
Est. primary completion date | May 7, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Men and women between 18 and 65 years of age. - Sign the informed consent form. - Know how to read, write and speak Spanish Exclusion Criteria: - Take supplements or multivitamin supplements or phytotherapeutic products (especially infusions) that interfere with the treatment under study up to 30 days before the start of the study. - Be lacto-vegetarian, lacto-ovo-vegetarian, or vegan. - Present intolerances and/or food allergies related to pterostilbene or the excipients. - Be a smoker. - Having received antibiotic treatment up to 30 days before the start of the study. - Present values of body mass index = 18kg/m^2 or = 35 kg/m^2. - Present some chronic disease with clinical manifestations: coronary heart disease, cardiovascular disease, diabetes, celiac disease, Crohn's disease, chronic kidney disease, cancer, autoimmune diseases (such as fibromyalgia), respiratory and/or gastrointestinal diseases that may compromise the absorption of the compound. - Clinical history of anemia. - Being pregnant or intending to became pregnant. - Be in breastfeeding period. - Being unable to follow the study guidelines. - Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days before inclusion in the study. |
Country | Name | City | State |
---|---|---|---|
Spain | Fundació Eurecat | Reus |
Lead Sponsor | Collaborator |
---|---|
Fundació Eurecat | Circe, S.L. |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bioavailability of Pterostilbene calculated by area under the curve (AUC 0-24) of plasma pterostilbene levels, both free and total. | Fasting pterostilbene levels in plasma will be determined by liquid chromatography coupled to mass spectrophotometry before consume the capsule with pterostilbene until 24 hours postprandially at 8 points after consuming the capsule (0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 24 hours).
Total PT will be quantified indirectly after hydrolysis of the conjugated glucuronide and sulfate metabolites to free PT in the presence of ß-glucuronidase and arylsulfatase in the plasma samples. |
At week 1, week 2 and week 3 | |
Secondary | Area under the curve (AUC 0-inf) of plasma pterostilbene levels, both free and total. | Fasting pterostilbene levels in plasma will be determined by liquid chromatography coupled to mass spectrophotometry before consume the capsule with pterostilbene until 24 hours postprandially at 8 points after consuming the capsule (0.5 hours, 1 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 24 hours).
Total PT will be quantified indirectly after hydrolysis of the conjugated glucuronide and sulfate metabolites to free PT in the presence of ß-glucuronidase and arylsulfatase in the plasma samples. |
At week 1, week 2 and week 3 | |
Secondary | Relative bioavailability of plasma pterostilbene levels (Frel). | Relative bioavailability of plasma pterostilbene levels, both free and total | At week 1, week 2 and week 3 | |
Secondary | Maximum plasma concentration (Cmax) | Maximum plasma concentration of pterostilbene, total and free. | At week 1, week 2 and week 3 | |
Secondary | Time for maximum plasma concentration (Tmax) | Time period for the maximum plasma concentration of pterostilbene, both total and free. | At week 1, week 2 and week 3 | |
Secondary | Half-life (T1/2). | Time taken for half the initial dose of pterostilbene, both total and free, administered to be eliminated from the body. | At week 1, week 2 and week 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05544786 -
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
|
Phase 1 | |
Completed |
NCT04744233 -
Bioavailability of Carotenoids From Orange Juice in a Cross-over Study in Healthy Subjects.
|
N/A | |
Completed |
NCT05561075 -
Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form (BIOPTERO)
|
N/A | |
Completed |
NCT03873909 -
Bioavailability of Carotenoids Present in Mamey Sapote (Pouteria Sapota (Jacq.) H. E. Moore & Stearn) Fruit
|
N/A | |
Completed |
NCT03353857 -
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
|
Phase 1 | |
Completed |
NCT05121506 -
A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults
|
Phase 1 | |
Completed |
NCT01267201 -
A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form
|
Phase 1 | |
Completed |
NCT02538393 -
Relative Bioavailability of Sorafenib Tablet for Oral Suspension
|
Phase 1 | |
Completed |
NCT05116982 -
Effect of Three Silicon Based Food Supplements on the Urinary Excretion of Aluminum and Other Metals (SILIAL)
|
N/A | |
Completed |
NCT04207372 -
Protein Digestibility of Whey and Zein.
|
N/A | |
Completed |
NCT01853800 -
Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet
|
Phase 1 | |
Completed |
NCT00714584 -
Pharmacokinetics of Naltrexone Following Intravenous and Oral Routes of Administration in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04876261 -
Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements
|
N/A | |
Completed |
NCT03886597 -
Nutritional Intervention With Table Olives in Healthy Volunteers
|
Phase 1/Phase 2 | |
Completed |
NCT05439408 -
Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03951025 -
Study of the Bioavailability of a Food Supplement Rich in Melatonin Administered Sublingually and Orally (MELATONIN)
|
Phase 2 | |
Completed |
NCT03984916 -
Study of the Bioavailability of Three Hesperidin Extracts.
|
N/A | |
Completed |
NCT02966704 -
Stable Isotope Method to Assess Dietary Protein Quality
|
N/A | |
Completed |
NCT02847117 -
Bioavailability of the Microconstituents of Natural Chios Mastiha in Healthy Adults.
|
N/A | |
Completed |
NCT03048110 -
Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction
|
Phase 1 |